RetinalGeniX Technologies, Inc. to Present at the Emerging Growth Conference Wednesday, October 26, 2022
October 24, 2022 13:05 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies, Inc. OTCQB: RTGN to Present at the Emerging Growth Conference. RetinalGeniX Technologies, Inc. (RTGN) is pleased to...
$12+ Billion Diabetic Retinopathy Market Size to Grow at a CAGR of 6.5% by 2028 | The Insight Partners
October 19, 2022 10:09 ET
|
The Insight Partners
New York, Oct. 19, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest market study on "Diabetic Retinopathy Market Size, Share, Trends, Growth Strategy and Forecast to 2028 – COVID-19...
Macular Degeneration Treatment Global Market Report 2022: Continued Development of Advanced Therapies Presents Opportunities
September 08, 2022 07:58 ET
|
Research and Markets
Dublin, Sept. 08, 2022 (GLOBE NEWSWIRE) -- The "Macular Degeneration Treatment Market Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global macular...
Vinay Mehindru, MD, MBA Appointed to RetinalGenix Technologies Inc. Board of Directors
July 26, 2022 06:15 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- RetinalGenix™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), announced today the appointment of Vinay Mehindru, MD, MBA to the...
RetinalGeniX Technologies, Inc. Acquires DNA/GPS Inc.
July 06, 2022 08:00 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), announced today the acquisition of DNA/GPS Inc.,...
Worldwide Macular Degeneration Treatment Industry to 2027 - Featuring Iveric Bio, Novartis and Panoptica Among Others
June 09, 2022 08:03 ET
|
Research and Markets
Dublin, June 09, 2022 (GLOBE NEWSWIRE) -- The "Macular Degeneration Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to...
Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
April 29, 2022 11:36 ET
|
Ocugen
MALVERN, Pa., April 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and...
Anterior Uveitis Treatment Market (2021 - 2026): Key Global Players Include Abbvie, Novartis and Regeneron
March 10, 2022 04:08 ET
|
Research and Markets
Dublin, March 10, 2022 (GLOBE NEWSWIRE) -- The "Anterior Uveitis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's...
Global Bionic Eye Market Research Report 2021 Featuring Nidek, Nano Retina, MetaModa, Pixium Vision, Monash Vision, iBionics & Optobionics
March 10, 2022 04:03 ET
|
Research and Markets
Dublin, March 10, 2022 (GLOBE NEWSWIRE) -- The "Global Bionic Eye Market, By Type (Implant v/s External), By Technology (Electronic v/s Mechanical), By End User (Hospitals, Ophthalmic Clinics,...
Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
December 09, 2021 07:28 ET
|
Ocugen
Gene therapy candidate has potential to address a large number of retinitis pigmentosa and Leber congenital amaurosis gene mutations with a single productTrial to start in Q1 2022 will enroll patients...